Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF
ERJ open research
; 2022.
Article
in English
| EuropePMC | ID: covidwho-1782002
ABSTRACT
The emergence and spread of 2019 coronavirus disease (COVID-19) are causing a growing global public health crisis. Despite advances in treatment, vaccination remains the best way to contain the pandemic [1]. Vaccines are currently available by means of conditional marketing approval, full approval and emergency use authorization pathways [2]. Evidence suggest that immunocompromised individuals including solid organ transplants recipients and patients under immunosuppressive treatment may have increased mortality from SARS-CoV-2 infection despite double dose messenger RNA (mRNA) vaccine regimens [3]. This is partially attributed to blunted immune responses to vaccination since only 38–54% of kidney and liver transplant recipients developed detectable SARS-CoV-2 antibodies following the second dose of mRNA vaccines [3, 4].
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Topics:
Vaccines
Language:
English
Journal:
ERJ open research
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS